FDA clears Neuronetics' neurostim for adolescents with depression
Neuronetics announced today that it received FDA clearance for the use of its NeuroStar therapy for adolescent patients.
Stay updated with breaking news from Pennsylvania Based Neuronetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neuronetics announced today that it received FDA clearance for the use of its NeuroStar therapy for adolescent patients.
Neuronetics announced today that a healthcare policy update from Aetna increases access to its NeuroStar therapy.
Neuronetics (Nasdaq:STIM) announced that it implemented improved internet connectivity capabilities across its NeuroStar platform.
Neuronetics (Nasdaq:STIM) announced today that it received FDA 510(k) clearance for its D-Tect MT accessory for the NeuroStar platform.
Neuronetics announced today that it entered into a commercial partnership with Alleviant Health Centers.